No Long-Term Benefit From Intravitreal Bevacizumab in Neovascular Glaucoma: Study

Intravitreal bevacizumab does not alter the long-term outcomes of neovascular glaucoma (NVG), so panretinal photocoagulation (PRP) should remain the mainstay of treatment, according to a retrospective study.
Reuters Health Information

Full Story →